Hansa Biopharma AB (publ) Earnings Date & Estimates

Hansa Biopharma AB (publ) (OTCMKTS:HNSBF) is a Swedish biopharmaceutical company focused on developing enzyme-based immunomodulatory treatments for patients with rare immunological conditions. Its research centers on therapies that selectively modify or remove disease-causing antibodies, with applications in transplantation, autoimmune diseases and other areas involving the immune system.

The company’s primary product is Idefirix (imlifidase), an enzyme that cleaves immunoglobulin G (IgG) antibodies. Idefirix received conditional marketing authorization in the European Union in 2020 for the desensitization of highly sensitized adult kidney transplant patients who are otherwise unlikely to receive a compatible organ. Hansa Biopharma is also evaluating imlifidase and related programs in additional transplant and immune-mediated indications.

Hansa Biopharma was founded in Sweden in 2007 under the name Hansa Medical and adopted its current name in 2017. The company is headquartered in Lund and operates internationally, with activities focused on Europe and other major biopharmaceutical markets. Its shares are listed in Sweden, and its American depositary trading symbol is HNSBF on the over-the-counter market.